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The tumor suppressor protein retinoblastoma (RB) is mechanistically linked to suppression
of transcription factor E2F1-mediated cell cycle regulation. For multiple tumor types, loss of
RB function is associated with poor clinical outcome. RB action is abrogated either by direct
depletion or through inactivation of RB function; however, the basis for this selectivity is
unknown. Here, analysis of tumor samples and cell-free DNA from patients with advanced
prostate cancer showed that direct RB loss was the preferred pathway of disruption in
human disease. While RB loss was associated with lethal disease, RB-deficient tumors had
no proliferative advantage and exhibited downstream effects distinct from cell cycle control.
Mechanistically, RB loss led to E2F1 cistrome expansion and different binding specificity,
alterations distinct from those observed after functional RB inactivation. Additionally,
identification of protumorigenic transcriptional networks specific to RB loss that were
validated in clinical samples demonstrated the ability of RB loss to differentially reprogram
E2F1 in human cancers. Together, these findings not only identify tumor-suppressive
functions of RB that are distinct from cell cycle control, but also demonstrate that the
molecular consequence of RB loss is distinct from RB inactivation. Thus, these studies
provide insight into how RB loss promotes disease progression, and identify new nodes for
therapeutic intervention.
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Introduction
The function of the retinoblastoma tumor suppressor (RB) in 
preventing tumor development relies in large part on the capac-
ity of this transcriptional corepressor to modulate E2F family 
transcription factor activity (1, 2). The E2F family consists of 8 
members, generally separated into 3 classes: typical activators 
(E2F1–E2F3a), canonical repressors (E2F3b–E2F6), and atypical 
repressors (E2F7 and E2F8) (2–4). Activator E2Fs use dimeriza-
tion partners to bind DNA at promoter regions of target genes, 
and induce transcriptional programs that result in a myriad of 
outcomes, including cell cycle progression and DNA repair 
(5–7). In conditions favoring cell cycle arrest (e.g., nutrient 
deprivation), activator E2Fs are held inactive through associa-
tion with RB (4), whereas pro-proliferative signals (e.g., growth 
factor stimulation) inactivate RB function through cyclin- 
dependent kinase–mediated (CDK-mediated) phosphorylation, 
thus releasing RB from activator E2F1 binding and derepressing 
E2F1 activity (8, 9). While RB is capable of modulating both acti-
vator and repressor E2Fs (2–4, 10), clinical observations to date 
suggest that the tumor suppressor role of RB depends on modu-
lation of activator (rather than atypical or repressor) E2F family 
members, suggesting divergent functions of the E2F transcrip-
tion factors in tumorigenesis (3).
Illustrating the importance of RB in restraining E2F1 func-
tion, pathways that abrogate RB-mediated E2F regulation are fre-
quently perturbed in human tumors. In a large subset of tumors 
retaining RB expression, alterations in cyclin-CDK pathways serve 
to inactivate tumor suppressor function. This is achieved either via 
upregulation of RB-inhibiting cyclin-CDK complex components 
(e.g., cyclin D1, CDK4, and cyclin E)(11–16) or through loss of 
CDK inhibitors such as p16INK4A and p27Kip1, both of which serve as 
tumor suppressors in their own right through this function (11, 15–
23). Underscoring the importance of RB inactivation in promoting 
cancer cell phenotypes, CDKs have been identified as therapeutic 
targets, and clinical trials for CDK inhibitors have shown promise 
across cancer types (NCT01291017, non–small cell lung carcino-
ma; NCT00141297, lymphoma; NCT01958021, MONALEESA-2, 
breast cancer) (11, 24–26), with palbociclib (CDK4/6 inhibitor) 
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are frequent in the majority of small cell lung cancers (29, 31, 32) 
as well as in the genitourinary cancers (15, 29, 30, 33–35), wherein 
30%–60% of bladder and advanced prostate cancers exhibit RB 
loss. In the case of prostate cancer, RB loss occurs predominantly 
at the time of progression from primary disease to aggressive, 
metastatic castration-resistant prostate cancer (CRPC) (30, 33, 
34, 36), indicating a role in promoting tumor progression rather 
than in tumor development.
Here, examination of RB pathway alterations in advanced 
prostate cancer revealed that CDK/cyclin/CDKi alterations are 
infrequent, and identified RB loss as the major mechanism of 
pathway disruption in human disease. Furthermore, RB status 
was readily traced through cell-free DNA analyses in human 
recently attaining FDA approval in hormone receptor–positive, 
HER2-negative, metastatic, or advanced breast cancer (27).
Distinct from tumors that preferentially retain RB expression 
but attenuate function through CDK-mediated RB inactivation, a 
subset of human malignancies preferentially abrogate RB through 
direct depletion of the protein. While tumor-specific proclivities 
for favoring RB retention and inactivation via CDKs versus RB 
loss have long been appreciated (15, 16, 28–30), the underlying 
basis for selectivity is unknown, and the relative impact on down-
stream E2F1 signaling and function remains undefined. RB loss 
is typically achieved through genetic alterations including either 
genomic deletion and loss of heterozygosity or somatic mutations 
that generate an unstable protein (8, 15, 29, 30). Such observations 
Figure 1. RB loss is frequent in CRPC and can be detected in circulating tumor DNA. (A) Mutual exclusivity plot indicating presence or absence of multiple 
alterations with each sample in the SU2C cohort (left) and frequency of indicated alterations in SU2C CRPC cohort (n = 144, right). CNA, copy number 
alteration. (B) Prevalence of specific RB alterations. (C) Schematic of ctDNA collection and sequencing of CRPC samples by the Karolinska Institute (top) 
and copy number alterations in RB pathway genes identified within the Karolinska ctDNA cohort through sequencing of a 1.3-Mb panel (bottom left) and 
prevalence of specific RB alterations (bottom right).
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1C, top). As shown in Figure 1C, RB copy number alterations were 
similarly frequent, with 56.4% (22/39) exhibiting loss of a single 
allele, 5.1% (2/39) loss of both alleles, and 2.5% (1/39) RB muta-
tion (Figure 1C, bottom). Further, with respect to alterations in 
AR as well as other RB pathway gene members, relative frequen-
cies were similar to what was observed in the SU2C/PCF cohort 
(Figure 1A), suggesting that liquid biopsy via ctDNA may provide a 
mechanism to assess RB status in this tumor type. Together, these 
data indicate that genomic RB loss is preferentially enriched as 
the main mechanism of RB pathway disruption in CRPC, further 
underscoring the importance of RB loss in late-stage disease.
RB loss is not associated with hyperproliferative indices. Pros-
tate cancer is well described as a heterogeneous disease (41). 
As such, RB status and the extent of tumor heterogeneity were 
assessed in available CRPC cohorts, wherein access to tissue 
for immunohistochemistry (IHC) was available. Briefly, 107 
CRPC tumor samples, collected by the Prostate Cancer Research 
Center at the University of Tampere, were examined for RB1 
status, AR amplification, PTEN status, and Ki67 positivity. As 
exemplified in Figure 2A (left) and quantified in the right panel, 
heterogeneity was observed in RB positivity. Tumors with the 
highest level of RB intensity (IHC scores 16–20 and 21–25) exhib-
ited less than 25% as much heterogeneity as tumor cells with-
out detectable RB, whereas a minority of tumors with reduced 
RB intensity (IHC scores 6–10 and 11–15, representing 21% of 
tumors analyzed) demonstrated the highest level of heterogene-
ity (Figure 2A, right). On balance, these data demonstrate that 
while heterogeneity in protein expression is observed, the major-
ity of RB-positive tumors in the current cohort exhibit clear RB 
staining across the specimens, allowing for segregation into RB-
positive versus RB-low tumor sets.
Given the known role of the RB/E2F pathway in regulat-
ing cell cycle progression (1), the impact of RB loss on prolifera-
tive indices was assessed. As shown, there was no significant 
correlation between Ki67 positivity and RB positivity (ρ = 0.14, 
P = 0.31; Figure 2B, left), suggesting that the aggressive nature 
of RB-deficient tumors cannot simply be attributed to a hyperp-
roliferative phenotype. As some heterogeneity was observed for 
RB staining, weighted RB intensity score was also considered, 
thus taking into account variations seen within tumor samples. 
Further supporting a role for RB outside of proliferative control, 
there was no significant correlation between weighted RB score 
and Ki67 positivity (ρ = 0.13, P = 0.35; Figure 2B, right). RB loss 
did not correlate with other clinically relevant alterations includ-
ing AR amplification or PTEN status (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI93566DS1), concordant with data from the 
SU2C/PCF cohort (Figure 1A) wherein AR amplification was 
largely observed in RB-intact tumors (30/44 tumors exhibiting 
AR amplification displayed intact RB). As neuroendocrine pros-
tate cancer (NEPC) is characterized by loss of RB coupled with 
increased proliferative rates (42–44), it is of note that tumors 
within this cohort did not exhibit prevalent neuroendocrine fea-
tures, as confirmed through pathologic assessment. Additionally, 
no association was determined between treatment and either RB 
or Ki67 positivity, suggesting that treatment type did not signifi-
cantly affect these correlates within this cohort (Supplemental 
specimens, thus identifying new ways to assign RB status in the 
clinical setting. Strikingly, RB depletion in human disease was 
not associated with a higher Ki67 index, indicating a role for the 
RB/E2F1 pathway in regulating processes distinct from cell cycle 
control and associated with lethal-stage disease. Subsequent 
mechanistic investigation used isogenic prostate cancer models, 
wherein RB could be differentially inactivated through depletion 
or through hormone-induced, CDK-mediated phosphorylation. 
Unbiased molecular interrogation uncovered a novel E2F1 cis-
trome and downstream engagement of transcriptional networks 
exclusively observed after RB loss, with binding specificity diver-
gent from canonically described E2F1 binding patterns. Addi-
tionally, E2F1 cistrome alterations elicited by RB depletion were 
seen to be distinct from those after phosphorylation-induced RB 
functional inactivation, providing needed insight into the basis of 
selectivity for RB loss versus CDK-mediated inactivation observed 
in human disease. Analyses of human CRPC tumor samples fur-
ther underscored the clinical relevance of RB loss–induced gene 
expression programs, which were significantly correlated with 
reprogrammed E2F1 binding identified herein. Taken together, 
the studies presented are, to our knowledge, the first to identify 
the consequence of RB loss, demonstrating molecular distinction 
from RB inactivation and illustrating the clinical relevance of RB 
loss–induced E2F rewiring.
Results
RB/E2F1 pathway disruption is frequent in and preferentially occurs 
through RB loss in CRPC. RB loss has been previously described to 
be prevalent in, enriched in, and causative for CRPC (34, 36–38). 
To expand analyses of the RB pathway to recent clinical findings, 
alterations in the androgen receptor (AR), RB, cyclin-CDK, and 
CDK inhibitor profiles were assessed using a cohort of CRPC tis-
sue from the Stand Up to Cancer/Prostate Cancer Foundation 
(SU2C/PCF) prostate cancer collection (Figure 1, A and B, and 
ref. 39). As expected based on the known role of the AR in pro-
moting disease progression (40), AR amplification was observed 
in 30.5% (44/144) of tumors analyzed. RB1 alterations were also 
highly prevalent, with 35.4% (51/144) exhibiting single-copy RB 
deletion, 1.4% (2/144) dual-copy RB deletion, and 0.7% (1/144) RB 
mutation (Figure 1, A and B). Strikingly, previous tumor profiling of 
late-stage disease has suggested that single-allele loss of RB is suf-
ficient to decrease RB transcript levels, supporting the significance 
of heterozygous RB loss observed in the current study (36). By 
contrast, RB-related pocket proteins p107 (RBL1) and p130 (RBL2) 
were rarely altered (1% and 12%, respectively; Figure 1, A and B). 
There was a similar paucity of alterations in other RB pathway 
genes, including CDK2, CDK4, CCND1 (cyclin D1), and CDKN2A 
(p16INK4A), demonstrating that loss of RB itself is the major mecha-
nism of RB pathway dysfunction in CRPC. Analyses of exclusivity 
further demonstrated that RB pathway alterations were typically 
specific to loss of the RB locus, reinforcing the concept that RB 
pathway dysfunction is frequent and is predominantly achieved via 
RB loss (Figure 1, A and B).
To further assess RB pathway status in advanced disease, a 
second, independent cohort was examined for RB pathway altera-
tions through isolation of cell-free tumor DNA (ctDNA) from 
CRPC patients, followed by sequencing of a 1.3-Mb panel (Figure 
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loss promotes CRPC phenotypes through mechanisms expanding 
beyond that of cell cycle control.
RB loss results in E2F1 repositioning and expansion of the E2F1 
cistrome. RB tumor suppressor function is thought to be contin-
gent on constraining E2F transcriptional activity (1). Given the 
impact of RB loss on CRPC development without influencing 
proliferative indices, coupled with the known increases in both 
E2F1 transcript and protein expression after RB loss, unbiased 
Figure 1B). Finally, an additional cohort of CRPC tumors was 
examined for RB and Ki67 expression via IHC (n = 57, confirmed 
to include no NEPC). Confirming results in Figure 1B, this second 
cohort of CRPC tumors also exhibited no correlation between 
Ki67 positivity and RB positivity (ρ = –0.061, P = 0.65) or weighted 
RB intensity (ρ = 0.047, P = 0.73), further suggesting a role for 
RB outside of canonical proliferative capacity (Figure 2C). Taken 
together, these findings indicate that in the clinical setting, RB 
Figure 2. RB loss elicits effects outside proliferative control. (A) Left: Representative images from CRPC tissue obtained via tissue microarray (University 
of Tampere) through IHC staining and RB status categorized by IHC score. IHC score = (frequency score × low intensity score) + (frequency × mid intensity 
score) + (frequency × high intensity score). Each core represents a ×6 original magnification, and each inset a ×40. Right: Grouped scatterplot illustrating 
quantity of RB loss within each grouping of IHC scores to illustrate RB heterogeneity. (B) Scatterplot of percent Ki67 positive versus percent of sample RB 
positive (left) or RB weighted intensity score (right) within the Tampere CRPC tumor cohort, with correlation shown (Spearman ρ and P value included). (C) 
Scatterplot comparing Ki67 positivity versus RB positivity (left) and weighted RB score versus percent Ki67 positive (right) within The Institute of Cancer 
Research CRPC tumor cohort.
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occurred less frequently at promoter regions (15.7%), while 31.2% 
of binding occurred at intronic regions and 32.6% at distal inter-
genic regions, further suggesting that the E2F1 sites gained upon 
RB loss largely occur outside promoter regions and may occur 
at enhancer regions (Figure 3B). Combined, these data provide 
some of the first insight into genome-wide E2F1 activity after RB 
loss, and demonstrate that RB depletion induces significant E2F1 
cistromic reprogramming.
Given these unexpected findings, the underlying mechanisms 
of differential E2F1 action were investigated. De novo motif analy-
ses were initially performed on each data set using a narrow win-
dow of 50 bp around the center of binding to specifically highlight 
the characteristics of DNA sequences underlying E2F1 binding 
(Figure 3C, schematic). As expected, motifs closely resembling 
the well-described canonical E2F1 binding motif were among the 
top most enriched motifs in shCON E2F1-bound regions (Figure 
3C, top). Interestingly, motif analysis using either the full E2F1 
cistrome identified upon RB knockdown (“shRB E2F1 binding”) or 
the subset of E2F1-gained regions seen exclusively in the RB loss 
condition (“shRB exclusive E2F1 binding”) showed enrichment 
for an abbreviated form of the canonical E2F1 motif lacking a 5′ 
poly-T stretch (Figure 3C, middle and bottom). Importantly, recent 
studies have shown E2F1 to have the ability to bind this truncated, 
previously described minimum-affinity E2F1 motif in specific con-
ditions (such as in the context of sustained E2F1 activity) (46, 48). 
Thus, these data suggest that in the context of intact RB, E2F1 is 
bound to primarily “high-affinity,” canonical E2F1 motifs, while 
RB loss drives E2F1 binding to a “minimum-affinity” motif.
To further assess the means by which E2F1 is directed to new 
sites upon RB loss, cooperating factor motifs were investigated. 
For these analyses, a broader window around the center of bind-
ing (1,000 bp) was applied to the E2F1 cistromes identified herein 
to examine the potential for changes in cooperative factor inter-
actions, contingent on RB status. As expected, enrichment for 
canonical E2F motifs was depleted upon RB knockdown (Figure 
3D, left, and Supplemental Figure 3), further supporting the idea 
that RB loss induces E2F1 binding distinct from canonical regions. 
Moreover, motifs belonging to the E2F family of transcription fac-
tors represented the majority of those enriched in binding sites 
exclusive to the control condition (Supplemental Figure 3). Addi-
tionally, as the E2F1 cistrome exhibited a marked expansion upon 
RB loss, motifs specifically enriched in these regions were iden-
tified. To identify potential novel functional interactions, motifs 
with enrichment detected in control conditions were removed, 
leaving those exclusively associated with gained binding upon 
RB loss (Figure 3D, right). Strikingly, motifs enriched exclusively 
adjacent to E2F1 binding after RB loss consisted of several tran-
scription factor binding motifs, including NF1, the TLX nuclear 
receptor, and AR. These findings not only provide the first evi-
dence for the role that RB depletion may have in driving E2F1 to 
minimum-affinity sites, but also suggest that novel cooperating 
transcription factors likely assist E2F1 to mediate phenotypes 
associated with RB loss.
E2F1 function is distinct after RB depletion versus RB inactivation. 
Dihydrotestosterone (DHT) is a potent ligand for AR in prostate 
cancer, and has been previously shown to induce RB hyperphos-
phorylation and subsequent inactivation through AR-dependent 
genome-wide assessment of E2F1 activity was prioritized (36). For 
these studies, well-characterized isogenic models of RB depletion 
in human prostate cancer cells (shCON and shRB, Figure 3A, top 
left; and refs. 36, 38) were used for E2F1 chromatin immunopre-
cipitation followed by deep sequencing (ChIP-Seq). Statistically 
significant E2F1 binding was identified in each isogenic line using 
the model-based analysis of ChIP-Seq (MACS2) algorithm with a 
stringent cutoff (Q < 0.01). With respect to shCON cells contain-
ing intact RB in castrate conditions, 11,670 peaks were detected 
for E2F1 (Figure 3A, bottom left, red circle), consistent with previ-
ous studies of E2F1 binding in other models (Supplemental Figure 
2A and refs. 45, 46). Interestingly, upon RB knockdown in these 
same castrate conditions, the total number of E2F1-bound regions 
was substantially increased to 26,431 sites, suggesting that RB 
loss increases overall E2F1 binding capacity (Figure 3A, bottom 
left, blue circle). It is of note that over 90% of E2F1 binding sites 
observed in the presence of RB were retained after RB loss, consis-
tent with the concept that E2F1 may exhibit gained functions upon 
RB loss. Further, commonly bound sites exhibited higher bind-
ing intensities upon RB knockdown, suggesting differential E2F1 
binding capacity even at commonly bound sites (Figure 3A, right). 
Together, these data support an expansion of the E2F1 cistrome 
rather than a simple relocation of the existing chromatin-bound 
E2F1 following RB loss.
To further assess the hypothesis that RB loss rewires the E2F1 
cistrome, sites of E2F1 binding gained upon RB loss were validated 
in an additional isogenic model of RB loss in the background of 
hormone therapy–sensitive LAPC4 cells (Supplemental Figure 
2B). Additionally, validation was also performed in LNCaP-abl 
cells, which are derived from LNCaP models, but incurred loss 
of RB as a function of the transition to castration resistance (47). 
As shown in Supplemental Figure 2B, E2F1 binding after RB loss 
was validated across these models at the indicated loci, suggesting 
that the E2F1 rewiring displayed in LNCaP models is maintained 
in model systems. Further, to determine the potential effect of 
the mechanism by which RB is modulated on E2F1 occupancy, 
recently described genome-wide E2F1 binding in the LNCaP-abl 
model was compared with E2F1 binding in the LNCaP shRB line. 
Strikingly, over 70% of the shRB E2F1 cistrome identified in the 
current study was validated by E2F1 binding in LNCaP-abl cells, 
further supporting the conclusion that the expansion in E2F1 bind-
ing capacity is consistent regardless of model system or mecha-
nism of RB modulation (Supplemental Figure 2C).
To investigate the chromosomal regions to which E2F1 was 
bound in each condition, cis-regulatory element annotation sys-
tem (CEAS) analysis was performed. As expected, in shCON 
cells harboring intact RB, 49.6% of the total binding was deter-
mined to occur at promoter regions (“shCON castrate,” Figure 
3B). Conversely, upon RB knockdown, E2F1-bound promoter 
regions comprised only 26.6% of the total binding events, while 
distal intergenic and intronic regions consisted of 21.9% and 
22.3% of the total binding, respectively (“shRB castrate,” Figure 
3B), suggesting that RB loss–induced E2F1 chromatin association 
may be enriched at sites other than promoters, such as enhanc-
ers. To more fully characterize the E2F1 sites gained exclusively 
after RB loss, CEAS analysis was performed (“shRB exclusive,” 
16,292 sites). Remarkably, these novel E2F1-bound regions 
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signaling (49, 50), thus serving as a mitogen in prostate cancer. To 
determine whether inactivation of RB through DHT stimulation is 
distinct from the changes seen upon RB depletion, E2F1 binding 
was assessed through additional ChIP-Seq binding studies after 
3-hour DHT stimulation, which resulted in subsequent RB phos-
phorylation and inactivation in shCON cells (Supplemental Fig-
ure 4A). Similarly to RB knockdown, DHT stimulation resulted in 
an expansion of the E2F1 cistrome, with 21,510 sites gained after 
DHT stimulation in comparison with control (Figure 4A, orange 
circle and red circle, respectively). To further address the impact 
of hormone action on E2F1 activity, estrogen-dependent breast 
cancer cells were stimulated with estradiol, which has been pre-
viously shown to induce RB phosphorylation through cyclin D1/
CDK4 activity (51–54), and the impact on E2F1 was assessed on 
a tested subset of sites exhibiting increased E2F1 occupancy after 
DHT stimulation. As shown, E2F1 binding after estradiol treat-
ment in MCF7 cells shows similar increases in occupancy, dem-
onstrating that hormone-induced E2F1 rewiring is not exclusive 
to prostate cancer (Supplemental Figure 4B). Additionally, while 
21,026 binding sites were commonly occupied between the RB-
loss (shRB castrate) and RB-inactivated (shCON 3-hour DHT) 
conditions, a significant fraction of E2F1 binding sites were dif-
ferentially occupied in both shRB castrate conditions (5,374 sites) 
and RB-inactivated conditions (10,592 sites) (Figure 4A). These 
findings additionally underscore the concept that the molecu-
lar repercussions of RB loss are distinct from those of mitogenic 
stimuli–induced RB inactivation. Further, as RB loss alone in cur-
rent models has been shown to significantly rewire E2F1 binding 
(Figure 3), the potential for androgen stimulation to further alter 
the E2F1 cistrome was tested. Interestingly, over 86% of sites 
identified in shRB models after DHT stimulation were common 
with those identified after RB loss alone, indicating that stimu-
lation with androgens does not significantly alter E2F1 binding 
after RB loss, consistent with RB loss itself being a major driver of 
CRPC (Supplemental Figure 4C).
Moreover, as E2F1 binding transitioned from canonical pro-
moter regions upon RB depletion (Figure 3B), changes in regu-
latory elements near E2F1 binding upon RB inactivation were 
assessed. As shown in Figure 4B, 46.4% of E2F1 binding occurred 
at promoter regions upon DHT-induced RB inactivation, similar 
to the 49.6% bound to promoters with intact RB (shCON castrate), 
whereas only 26.6% of binding was seen at promoters upon RB 
depletion (shRB castrate). Consistently, only 9.5% and 9.0% of 
the total binding was seen at intronic and distal intergenic regions 
upon RB inactivation, respectively, as compared with 22.3% and 
21.9% after RB depletion. Together, these data suggest that while 
DHT inactivation of RB induces an increase in overall E2F1 bind-
ing, this cistrome is distinct from that seen after RB loss with 
respect to both overall binding site overlap and specific changes in 
enrichment of cis-regulatory elements.
Because of the changes seen in regulatory elements associ-
ated with E2F1 occupancy between the 2 conditions, binding char-
acteristics after RB depletion versus inactivation were assessed 
through de novo motif enrichment to highlight changes in DNA 
sequences underlying differential binding. While the CTCF bind-
ing motif was enriched in both data sets, other key distinctions 
were observed. Whereas the E2F1 cistrome after RB inactivation 
was enriched for E2F1 and FOXM motifs (Figure 4C, top right), 
E2F1 binding after RB depletion was most associated with nuclear 
receptor motifs (Figure 4C, bottom right). Together, these find-
ings further indicate that RB inactivation through DHT stimula-
tion and RB loss elicit divergent E2F1 binding profiles, with regard 
to both promoter preference and binding specificity.
Chromatin accessibility is equivalent regardless of RB status. 
RB and E2F1 have both been described to interact with chroma-
tin remodelers in various cellular contexts to alter the chromatin 
landscape (48, 55–58). Coupled with the finding that E2F1 bind-
ing is significantly expanded after RB loss, and that this expansion 
is distinct from E2F1 binding after DHT-induced RB inactivation, 
the potential for differential chromatin accessibility was assessed 
using assay for transposase-accessible chromatin with high-
throughput sequencing (ATAC-Seq). ATAC-Seq uses hyperactive 
Tn5 transposase activity to preferentially insert adapters (used for 
high-throughput sequencing) in regions of open chromatin. Thus, 
in order to assess chromatin availability in conditions displaying 
the greatest changes in E2F1 binding, ATAC-Seq was performed in 
shRB and shCON cells in castrate conditions, as well as in shCON 
cells in DHT-stimulated conditions. As seen in Figure 5A, regions 
of open chromatin were detected across conditions in both pro-
moter and distal regions of the indicated E2F1 targets, consistent 
with the capacity for this assay to identify regions of open DNA.
To detect regions of accessible DNA on a genome-wide scale, 
ATAC-Seq peaks were called in each condition, applying the irre-
producible discovery rate (IDR) framework in order to ensure 
high-confidence peaks. The majority of peaks identified were 
present in all tested conditions tested (7,308 sites; Figure 5B, left), 
suggesting that while there are minor changes in open chromatin 
peaks observed, the chromatin landscape remains highly similar 
regardless of RB status or androgen stimulation. Further support-
ing this conclusion, normalized ATAC-Seq signal remained pres-
ent across the merger of all peaks identified in all conditions, with 
the highest binding intensity seen in DHT-induced RB-inactivated 
conditions, likely due to changes outside RB/E2F1 activity, and the 
weakest in castrate control conditions (Figure 5B, right). Finally, 
principal component analysis was performed to assess variability 
between the conditions on a genome-wide scale. As shown in Fig-
ure 5C, each condition displays similar segregation along principal 
component 1 (x axis), which represents over 90% of the variance 
seen across the samples (Figure 5C and Supplemental Figure 5), 
further supporting the similarity between conditions with respect 
to open chromatin. Together, these data demonstrate that the 
overall state of chromatin accessibility remains similar after RB 
Figure 3. RB loss expands E2F1 binding capacity and repertoire of associ-
ated cis-binding elements. (A) Overlap of binding in shRB or shCON cells in 
castrate conditions. (B) Cis-regulatory element analysis of shCON or shRB 
binding data sets determined using CEAS package. Percent of total binding 
is shown in indicated data sets. (C) De novo motif enrichment using a 50-bp 
window around the center of binding. Enrichments specific to the data set 
are shaded in the Venn diagrams with P values shown for each motif. (D) 
Left: JASPAR (http://jaspar.genereg.net/) E2F1 motif was used to determine 
enrichment in shCON E2F1 or shRB E2F1 binding data set using a 1,000-bp 
window around the center of binding. Right: Top motifs enriched only in 
shRB exclusive data set using known motifs and a 1,000-bp window around 
the center of binding and representative histogram of motif enrichment.
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RB loss. As such, RNA from shCON and shRB isogenic pairs was 
isolated and RNA sequencing (RNA-Seq) performed. Significant 
transcriptional alterations were seen in castrate conditions, with 
1,423 genes upregulated and 1,496 downregulated genes observed 
after RB loss (adjusted P value < 0.05; Figure 6A). Consistent with 
the role of E2F1 as a transcriptional activator, RB loss was seen to 
induce the transcription of a number of different genes, including 
previously described E2F1 targets such as PCNA and PLK1 (Sup-
plemental Figure 6A). The abundance of transcripts downregu-
lated upon RB knockdown was less anticipated, and suggests that 
E2F1 may directly or indirectly serve as a transcriptional repres-
sor as well (Figure 5A, left, and Supplemental Figure 6A). To test 
RB loss–induced transcriptional changes across model systems, 
LAPC4 isogenic models (shCON/shRB) and LNCaP-abl models 
were also assessed for transcriptional changes (both up- and down-
depletion or inactivation, and support the idea that E2F1 rewiring 
is likely not due to widespread global alterations in open chroma-
tin and indiscriminate or opportunistic E2F1 binding.
Delineation of the RB loss–induced transcriptome. The obser-
vations that RB loss in CRPC is frequent and not correlated with 
a hyperproliferative phenotype (Figures 1 and 2), coupled with 
the finding that RB loss induces expansion of the E2F1 cistrome 
(Figure 3) distinct from that seen with inactivation of RB and via 
mechanisms outside differential chromatin accessibility (Figures 
4 and 5), suggest that RB loss alters E2F1 activity in prostate can-
cer, and likely results in differential regulation of transcriptional 
networks that promote disease aggressiveness. Strikingly, there 
have been few reports that assess genome-wide E2F1 activity 
and resultant transcriptional outcomes in any tumor type, and to 
our knowledge no genome-wide assessment of E2F1 activity after 
Figure 4. DHT-mediated RB inactivation results in distinct E2F1 reprogramming. (A) Overlap of binding in LN shCON cells in androgen-stimulated condi-
tions (3-hour DHT) with shCON or shRB cells in castrate conditions. (B) Chromosomal enrichment analysis of castration-treated or DHT-stimulated cells, 
represented as percent of total binding in each indicated data set. (C) De novo motif enrichment in indicated data sets using a 50-bp window around the 
center of binding using binding exclusive to either the shCON DHT-stimulated condition (top) or the shRB castrate condition (bottom).
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expression after CDK4/6 inhibitor treatment compared with cas-
trate conditions, suggesting that castrate conditions fully activate 
RB in the context examined (Supplemental Figure 6B). Finally, 
as DHT stimulation was seen to have little added effect on E2F1 
binding after RB loss alone (Supplemental Figure 4B), the potential 
for DHT to further deregulate the RB loss–induced transcriptome 
was tested. As shown in Figure 6B, no significant alterations 
were identified in shRB cells in castrate versus DHT-stimulated 
conditions, consistent with the supposition that RB loss itself 
re presents the main mechanism of transcriptional deregulation.
regulated) at the indicated targets. Targets assessed were seen to 
exhibit highly concordant changes in gene expression after RB 
loss, as compared with LNCaP isogenic lines, thus indicating a 
high degree of reproducibility across multiple model systems and 
mechanisms of RB loss (Supplemental Figure 6A). Additionally, to 
assess the potential for CDK4/6 inhibitors to enhance transcrip-
tional alterations identified in RB loss versus RB-intact con ditions, 
shCON cells were treated with a CDK4/6 inhibitor (palbociclib), 
and gene expression in a subset of RB loss–induced targets was 
examined. As expected, no significant effect was seen on gene 
Figure 5. Chromatin landscape is consistent regardless of RB status. (A) 
ATAC-Seq signal at indicated loci for shCON and shRB in castrate condi-
tions and shCON after DHT treatment using Integrative Genomics Viewer 
(http://software.broadinstitute.org/software/igv/home). (B) Venn 
diagram representing overlap in ATAC-Seq peaks (left) and ATAC-Seq 
signal across all peaks in all conditions (right). Peak calling was performed 
using the ATAC-Seq ENCODE pipeline, and highly concordant peaks across 
replicates were identified using IDR and subsequently used for Venn 
diagram and signal profile generation. (C) Principal component analysis 
for ATAC-Seq replicates.
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signaling, the RB loss–induced transcriptome was significantly 
enriched for this gene signature (Supplemental Figure 6D). 
Taken together, the transcriptional changes seen upon RB deple-
tion demonstrate gained E2F1 activity in the absence of canoni-
cally required stimuli to elicit transcriptional profiles known to 
be vital for aggressive disease.
To determine the potential mechanism driving the transcrip-
tional changes observed after RB depletion, genes associated 
with changes in E2F1 binding after RB loss were assessed using 
a guilty-by-association approach (68). Briefly, to identify genes 
potentially regulated by novel binding, as the majority of gained 
binding was seen away from promoter regions, a 30-kb window 
around gene transcriptional start sites was used, with genes within 
this window deemed putatively regulated by E2F1 binding exclu-
sive to each condition (shCON castrate, shRB castrate; Figure 6D, 
left). Using this approach, 317 genes showed exclusive E2F1 bind-
ing within this window with RB intact, while 599 genes harbored 
a gained E2F1 site in both RB-intact and RB-depleted conditions, 
and 12,269 genes were associated with a gained E2F1 binding site 
exclusive to the RB loss condition (Figure 6D, middle). Next, genes 
with binding exclusive to RB loss (12,269 genes) were overlaid 
with those exhibiting differential expression from the RNA-Seq 
previously described in Figure 6A to determine whether the novel 
E2F1 binding seen after RB loss was associated with the altered 
transcriptional profiles observed after RB depletion (Figure 6D, 
right). To more accurately assess this, GSEA was performed 
using the genes exhibiting gained E2F1 binding accompanied by 
changes in gene expression, and significantly altered pathways 
were compared with those identified from only transcriptional 
data in Figure 6C. As shown, half of the attenuated pathways 
identified from the RNA-Seq alone were also identified using 
those genes with altered expression and gained E2F1 binding 
(Figure 6E, left), suggesting that a subset of the pathways with 
reduced enrichment are likely attributable to novel E2F1 binding– 
mediated repression. Additionally, when pathways enriched upon 
RB loss were investigated, 70% of the pathways initially identi-
fied using RNA-Seq alone were recapitulated when genes with 
altered expression and gained E2F1 binding were analyzed (Fig-
ure 6E, right). As the RB loss–driven transcriptome has heretofore 
remained undefined, the finding that the majority of the pathways 
induced after RB depletion were associated with a gain in E2F1 
binding is striking, and suggests a fundamental role for the novel 
E2F1 cistrome identified herein as a putative driver of these path-
ways vital for lethal tumor phenotypes.
Evidence of expanded E2F1 activity in clinical CRPC. To assess 
the clinical relevance of the newly identified transcriptional net-
works and E2F1 repositioning driven by RB loss, genes were priori-
tized through iterative processes for further analyses. Briefly, genes 
exhibiting differential expression upon RB loss were segregated 
into 2 categories to determine the specific importance of gained 
E2F1 binding capacity clinically: (a) genes with any E2F1 binding 
within 30 kb of the transcriptional start site and (b) genes specifi-
cally associated with gained E2F1 binding after RB loss (Figure 
6D). These 2 gene sets were then queried against gene expression 
data from the SU2C/PCF CRPC tumor cohort. Genes exhibiting 
expression changes upon RB loss in the SU2C/PCF cohort concor-
dant with our model were identified, resulting in a list of genes with 
To identify pathways that were deregulated upon RB loss, gene 
set enrichment analysis (GSEA) was performed, using hallmark 
gene sets from the Molecular Signatures Database (MSigDB). Few 
pathways were attenuated after RB depletion, despite the total 
number of genes altered in this category, underscoring the focused 
nature of E2F1 activity to elicit specific transcriptional programs. 
Pathways with attenuated enrichment include those that have 
been previously shown to interplay with the RB/E2F1 axis, such 
as epithelial-mesenchymal transition, hedgehog signaling, and 
myogenesis (Figure 6C, left; normalized enrichment score < –1.3) 
(59–64). Conversely, a number of clinically relevant pathways 
were enriched upon RB loss, including canonical E2F targets, Myc 
targets, mitotic spindle, and DNA repair (Figure 6C, right; normal-
ized enrichment score > 1.3). The observed induction of E2F tar-
gets upon RB depletion was especially striking given the absence 
of mitogenic stimuli typically required to promote transcription of 
these targets. Similarly, the increased transcriptional output for 
genes responsible for DNA repair suggests that putative gained 
functions of E2F1 upon RB depletion may drive dysregulation of 
genes controlling DNA damage response, even in the absence of 
DNA damage. Further, Myc has been shown in other tumor types 
to interact with E2F3 to bring about specific transcriptional pro-
grams important for cancer progression (65). Here, transcriptional 
data provide some of the first evidence for RB loss–driven induc-
tion of Myc targets in prostate cancer, validated in multiple model 
systems, suggesting that E2F1 rather than E2F3 may interact with 
Myc in this disease type (Supplemental Figure 6A).
Further, to test for concordance with previously described 
signatures of RB loss of function, GSEA was performed using a 
previously described “RB loss signature” (66). As shown in Sup-
plemental Figure 6C, genes in the RB loss signature were highly 
enriched within RB loss–induced transcriptional alterations 
seen in the current study, suggesting that RB loss in the cur-
rent study encompasses previously described gene expression 
changes after functional RB inactivation. Finally, as previous 
studies have shown AR targets to be impacted by RB loss (36), 
a signature of androgen response generated from patient tissue 
was assessed for enrichment in the current model (67). Consis-
tent with the previously described role for RB loss to alter AR 
Figure 6. Genome-wide assessment of RB loss reveals novel functions 
and distinct transcriptional profiles. (A) Smear plot for RNA-Seq in 
castrate conditions (shRB vs. shCON) using Empirical Analysis of Digital 
Gene Expression Data in R (edgeR) to define differentially expressed 
genes. Genes highlighted in red represent statistically significant dif-
ferential expression (adjusted P value < 0.05). CPM, counts per million 
reads mapped (B) Smear plot for RNA-Seq in shRB models (castrate vs. 
DHT-stimulated conditions) using edgeR to define differentially expressed 
genes. Genes highlighted in red represent statistically significant differen-
tial expression (adjusted P value < 0.05). (C) GSEA for enriched pathways 
upon RB loss (normalized enrichment score [NES] > 1.3). Briefly, transcrip-
tional data from RNA-Seq output were examined for overrepresented 
pathways using the Hallmarks gene set collection (Molecular Signatures 
Database, MSigDB). Pathways de-enriched (left) or enriched (middle) 
after RB loss are shown, and leading-edge plot for E2F targets (right). (D) 
Schematic of binding to gene association with overlay with gene expres-
sion data. (E) Intersection of pathways identified from RNA-Seq alone 
compared with those identified using the intersection of RNA-Seq and 
ChIP-Seq results (NES > 1.3).
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ity to cluster tumors exhibiting RB loss together in the SU2C/PCF 
cohort (P = 0.002, odds ratio = 3.7) compared with those genes 
with the presence of an E2F1 binding site (not significant), sug-
gesting that genes exhibiting RB loss–induced differential expres-
sion and expanded E2F1 binding in this model better predict for 
RB loss in clinical samples than the simple presence of an E2F1 
site alone (Figure 7B and Supplemental Figure 7A). As such, these 
findings demonstrate that the capacity of RB loss to reprogram 
E2F1 binding capacity and the resultant downstream transcrip-
tional networks occurs in clinically lethal CRPC. Furthermore, 
E2F1 binding (present or exclusively gained after RB loss), differ-
ential expression in models of RB loss, and differential expression 
in clinical patient samples after RB loss (Figure 7A).
To examine the clinical relevance of RB loss–induced E2F1 
reprogramming and altered transcriptional output identified in 
the present study, hierarchical clustering was performed using 
genes identified in Figure 6A and transcriptional data from the 
SU2C/PCF CRPC tumor cohort (Figure 7A). Importantly, genes 
specifically exhibiting gained E2F1 binding sites upon RB loss 
(deemed “E2F1 expanded signature”) displayed a significant abil-
Figure 7. Clinical assessment of RB loss in CRPC reveals novel E2F1-gained cistrome-driven gene signature. (A) Differentially expressed genes from 
RNA-Seq were overlaid with ChIP-Seq binding studies into those genes that were associated with an E2F1 binding site, or those genes associated with a 
gained E2F1 binding site (seen only upon RB loss). Genes in each of these categories were then queried against CRPC patient data from the SU2C cohort, 
and those genes from each category with expression concordant with the initial model identified. TSS, transcriptional start site. (B) Hierarchical clustering 
of normalized expression data of concordant genes from 144 SU2C CRPC samples (1 – Pearson’s correlation coefficient for columns and Euclidean distance 
for rows were used as distance measures). The annotation track reports the genomic status of RB1 (black, SCNA alteration; white, no SCNA alteration) and 
genes used for heatmap generation identified through analysis in A. (C) GSEA was performed on the 80-gene signature identified in B, in order to identify 
which pathways were likely to drive signaling in CRPC patients.
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pathway disruption in this malignancy. While additional stud-
ies will be used to assess the potential for altered AR activity 
to impact RB phosphorylation status in late-stage disease, data 
in the present study reveal no correlation between loss of RB 
and increased Ki67 in CRPC, demonstrating that RB loss is not 
sufficient to alter proliferation and further suggesting that the 
capacity of RB depletion to drive aggressive tumor phenotypes 
occurs via functions distinct from cell cycle control (Figure 2, 
B and C). While investigation of associations between RB path-
way status and Ki67 in the clinical setting is limited, the concept 
that RB loss induces biological effects distinct from cell cycle 
deregulation has precedent in human tumors. For instance, 
in a recent study of lung adenocarcinoma (70), RB-negative 
tumors were seen to have no correlation with Ki67 positivity 
(P = 0.33), further supporting findings in the current study that 
suggest RB loss is not associated with hyperproliferative phe-
notypes (Figure 2, B and C). Conversely, in other tumor types 
where RB expression is retained but inactivated by phosphoryla-
tion, correlation with a higher proliferative index was observed, 
including studies in diffuse large B cell lymphoma, in Burkitt’s 
lymphoma wherein p27Kip1 is lost (71, 72), or in luminal A and 
triple-negative breast cancer where p16INK4A loss occurs (21). 
In concert with the data herein, these findings shift thinking 
with regard to RB pathway disruption, and provide compelling 
clinical evidence to support the contention that RB loss is mech-
anistically distinct from RB inactivation.
The discovery that RB loss elicits distinct effects compared 
with RB functional inactivation in clinical tumor samples is strik-
ing, as RB loss alone is sufficient to induce CRPC phenotypes (36) 
and loss of RB was seen to be the main mechanism of RB pathway 
disruption in the current study. Further, as models of RB loss are 
reliant on E2F1 for castration-resistant growth (36), provision of 
a putative mechanism for E2F1 in mediating these downstream 
phenotypes is significant. Toward this end, a key discovery herein 
demonstrated, through use of multiple model systems, is that 
the E2F1 cistrome is differentially expanded after RB loss, sug-
gesting that E2F1 binding is not in fact a static phenomenon. 
Further, studies presented here demonstrate, for the first time to 
our knowledge, that RB loss (as compared with RB inactivation) 
significantly expands the putative repertoire of E2F1-regulated 
target genes through binding outside of promoter regions, with 
16,292 E2F1 sites gained after RB loss, 31.2% and 32.6% of binding 
occurring in intronic and intergenic regions, respectively (Figure 3, 
A and B). As E2F1 was previously thought to regulate target genes 
through promoter binding (2), these findings open new avenues of 
understanding for discerning the function(s) of E2F1 in promoting 
disease progression when RB is lost. Moreover, as discerning the 
molecular basis of expanded E2F1 binding is of interest, it is strik-
ing that chromatin accessibility was largely unchanged regard-
less of RB status, suggesting that the mechanisms underlying the 
altered E2F1 cistrome lie outside simple opportunistic binding 
due to changes in open chromatin (Figure 5). Thus, current inves-
tigation is focused on discerning the molecular basis of expanded 
E2F1 binding upon RB loss.
Data herein further implicate gained E2F1 chromatin local-
ization outside canonical promoter regions, through potential 
use of a noncanonical minimum-affinity binding motif previ-
interrogation of the resulting gene signature further highlights 
the protumorigenic consequence of RB loss that is distinct from 
cell cycle control. Using GSEA analyses, pathways enriched within 
this signature included not only E2F targets, but also networks 
regulating Myc function, mitotic spindle integrity, and p53 
response (Figure 7, B and C). Further, to assess how the E2F1 
expanded signature identified in the current study compared with 
“ideal” clustering for RB loss in the SU2C/PCF cohort, supervised 
analysis was performed using only SU2C/PCF gene expression 
data to identify genes significantly changed in RB-altered ver-
sus RB wild-type samples. As shown in Supplemental Figure 7B, 
clustering resulting from supervised analysis was comparable to 
that generated using the E2F1 expanded signature. Moreover, 
genes contained in the E2F1 expanded signature were seen to be 
significantly enriched within the gene set resulting from super-
vised analysis by both GSEA (FDR = 0.003) and Fisher’s exact test 
(P < 1 × 10–10) (Supplemental Figure 7C), further supporting the sig-
nificance of gained E2F1 binding upon RB loss within the SU2C/
PCF cohort. Together, these data demonstrate that the expanded 
E2F1 cistrome identified herein occurs in RB-deficient clinical 
CRPC, providing the first insight into the mechanisms by which 
RB loss induces aggressive tumor phenotypes, independent of cell 
cycle dysregulation (Figure 8).
Discussion
The importance of the RB/E2F1 pathway in tumor suppression is 
compellingly illustrated by the frequency of pathway disruption in 
human malignancy and association with poor outcome (34–36, 38, 
69). However, the underlying basis for tumor-specific RB inactiva-
tion versus RB loss remains unknown. The present study reveals 
the molecular consequences of RB loss in human disease, and 
identifies unique molecular and cellular outcomes that promote 
tumor aggressiveness. Key findings include: (a) in CRPC, altera-
tions of the RB pathway are preferentially enriched for RB loss, 
which is frequently observed in both tumor samples and ctDNA 
from patients with advanced disease (Figure 1); (b) loss of RB is 
associated with advanced disease but is independent of altered 
proliferative indices, suggesting roles for RB outside cell cycle con-
trol (Figure 2); (c) RB loss expands and reprograms E2F1 chroma-
tin occupancy (Figure 3); (d) the molecular consequence of RB loss 
is distinct from that observed after RB inactivation (Figures 3 and 
4); (e) gained E2F1 binding capacity is not likely to be the result of 
widespread, global changes in chromatin accessibility (Figure 5); 
(f) RB depletion induces distinct transcriptional networks that are 
highly associated with gained E2F1 activity after RB loss (Figure 
6); and (g) the identified transcriptional programs driven by the 
gained activity of E2F1 upon RB loss (“E2F1 expanded signature”) 
occur in clinical, end-stage disease (Figure 7). Taken together, 
these findings define the molecular and tumor-associated con-
sequences of RB loss in human malignancy, and provide the first 
insight into the putative mechanism of RB loss–induced transcrip-
tional alterations in advanced cancers.
As demonstrated in both preclinical modeling and clinical 
samples, it is clear that reprogrammed E2F1 activity after RB 
loss elicits biological effects distinct from cell cycle control. 
As described herein, analyses of 2 large, independent CRPC 
cohorts indicate that loss of RB is the main mechanism of RB 
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Together, these findings bring about broad new understanding 
of the biological impact of RB loss on tumor phenotypes that pro-
mote progression; ongoing studies are directed at discerning the 
relative contribution of each newly identified E2F1-associated 
network to biological outcomes and disease progression.
Finally, findings in the current study identify a signature of 
genes predictive for RB loss in CRPC, associated with gained E2F1 
binding in the model systems used in the current study (Figure 
7). Remarkably, only genes exclusively associated with expanded 
E2F1 binding driven by RB loss clustered CRPC tumors deficient 
in RB expression, while the simple presence of E2F1 was unable to 
predict for the same alteration in the tumor samples, suggesting 
that E2F1 binding gained after RB loss is significantly relevant to 
CRPC phenotypes (Figure 7B and Supplemental Figure 7). These 
data identify, for the first time, a set of targets induced through 
novel E2F1 binding, and specifically altered by RB loss in human 
disease. Importantly, higher stringency used to define differen-
tially expressed genes in the model systems used herein identified 
stronger concordance between in vitro expression data and gene 
expression profiles from patient tumor samples, further highlight-
ing the clinical relevance of the targets identified in these mod-
els. It is of note that the current study used models of AR-positive 
disease in addition to non-neuroendocrine CRPC tumor samples 
(SU2C/PCF), as recent studies suggest that RB loss may yield dis-
tinct effects in tumors acquiring neuroendocrine phenotypes via 
RB loss (39, 87). Further, as RB loss of expression has been shown 
in the current study to elicit molecular effects distinct from those 
driven by phosphorylation-induced inactivation, it is likely that 
this RB loss–induced gene signature (E2F1 expanded signature) 
could be applied to other disease types to indicate similar E2F1 
reprogramming. Additionally, pathway analyses for genes within 
this signature were highly consistent with those identified using 
binding and gene expression in the model systems alone, suggest-
ing a coordinated set of pathways preferentially driven by E2F1 
binding both in vitro and in advanced disease (Figure 6E and Fig-
ure 7C). Thus, the identification of specific RB loss–altered gene 
targets within pathways that drive CRPC phenotypes represents 
potential targets for further therapeutic intervention.
Taken together, molecular interrogation of E2F1 function 
after RB loss suggests a paradigm shift, whereby E2F1 bind-
ing is directed away from promoter regions, eliciting marked 
reprogramming of E2F1 chromatin-binding capacity and E2F1- 
associated transcriptional programs. Further, data herein cou-
pled with clinical studies indicate that E2F1 activity after RB loss 
is distinct from E2F1 activity after phosphorylation-induced RB 
inactivation, suggesting a distinction in how RB protein deple-
tion and loss of function through inactivation impact human 
malignancy. Finally, data in the current study nominate a novel 
gene signature driven by RB loss and gained E2F1 function, 
which is altered in late-stage prostate cancer and is predictive 
for RB loss in advanced disease (“E2F1 expanded signature”), 
further nominating E2F1 as a critical driver of CRPC phenotypes 
in this disease state. Together, these findings contribute new 
insights into the molecular mechanisms underpinning RB loss– 
dependent CRPC phenotypes, and define a novel E2F1 cistrome 
upon RB loss associated with an altered transcriptional program 
with applicability to multiple malignancies.
ously identified in studies assessing E2F1 functional domains in 
addition to those investigating E2F1 function in liver cancer (refs. 
46, 48, and Figure 3, C and D). Interestingly, this abbreviated, 
minimum-affinity E2F motif was found to be enriched in regions 
of AR binding as well as under epigenetic marks of active transcrip-
tion (H3K4me3) in recent studies in CRPC tissue (67), suggesting 
that E2F1 may preferentially interact with AR in CRPC through 
gained binding capacity at minimum-affinity regions. Moreover, 
motifs for binding of putative cooperating transcription factors of 
clinical relevance were enriched in conjunction with gained E2F1 
occupancy after RB loss (Figure 3D), including those associated 
with: NF1 factors, which can modulate AR function (73, 74); TAL-1 
(SCL), which influences pioneer factors that modulate AR func-
tion (75, 76); and the half-site for AR itself. Further, de novo motif 
analyses additionally implicate AR, as the RB loss–induced E2F1 
cistrome was enriched for an AR half-site (Figure 4C) (77). These 
observations suggest the intriguing concept, currently being test-
ed, that E2F1 reprogramming may influence AR activity, or vice 
versa. Finally, gained E2F1 binding is associated with enrichment 
for the orphan nuclear receptor TLX, which promotes prostate 
cancer growth and is highly expressed in advanced disease (78). 
Combined, these data indicate that loss of RB expands E2F1 activ-
ity in a manner distinct from RB retention/inactivation, allowing 
E2F1 to localize to new, distal genomic sites governed distinctly 
from promoter regions (Figures 3 and 4).
Consistent with the molecular identification of the differ-
ential RB-mediated E2F1 cistrome, a distinct transcriptome was 
defined, which was driven specifically by RB depletion and highly 
associated with E2F1 reprogramming in the context of RB loss 
(Figure 5). Discovery of transcriptional networks that are uniquely 
associated with expanded E2F1 occupancy underscored activi-
ties of E2F1 beyond those linked to cell cycle control (Figure 6, 
C and E), and identified heretofore underappreciated functions 
of E2F1. Notably, E2F1 reprogramming appears to be associ-
ated with increased Myc target gene expression, which is known 
to promote disease progression and poor outcome in this tumor 
type (79, 80). These findings may also provide a molecular basis 
for recent observations in intestinal cancers, wherein RB pathway 
loss induces E2F3 and Myc cooperation (65). As such, while E2F3 
does not significantly correlate with RB loss in CRPC (36), the 
potential for effects on the RB loss–induced E2F3 cistrome rep-
resents an intriguing node of future study. In addition to associa-
tions with Myc function, it is striking that E2F1 reprogramming 
enriches pathways promoting DNA damage and repair, given 
recent findings linking DNA repair alterations with disease pro-
gression and acquisition of aggressive tumor phenotypes (81–86). 
Figure 8. Summary of E2F1-induced alterations upon RB loss in CRPC. (A) 
Circos plot represents ChIP-Seq, RNA-Seq, and clinical alterations identi-
fied in the current study. From outer ring to inner ring, the levels represent: 
(i) differentially expressed genes identified through RNA-Seq after RB loss 
(purple/green heatmap), (ii) E2F1 binding exclusive to shCON condition 
(blue histogram), (iii) binding common to shCON and shRB conditions 
(gray), (iv) E2F1 binding exclusive to shRB condition (red histogram), and 
(v) genes exhibiting differential expression after RB loss, associated with 
gained E2F1 binding, and concordant with SU2C clinical expression data. 
(B) Hypothesized model of RB loss in CRPC.
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with a P less than 0.05 considered significant. Significance for ChIP-
Seq and differential gene expression for RNA-Seq were calculated by 
the indicated software as described above. Motif analysis significance 
was calculated by the Homer suite, with a P less than 1 × 10–20 consid-
ered significant. Concordance with the study model and SU2C/PCF 
cohort was calculated as described above. Individual thresholds for 
significance are additionally indicated in applicable figure legends. 
Data are expressed as mean ± SD unless otherwise indicated.
Study approval. Use of patient and clinical material was approved 
by the ethical committee of Tampere University Hospital and the 
National Authority for Medicolegal Affairs (Helsinki, Finland), by the 
Marsden Ethics Committee (London, United Kingdom, CCR-2472), 
by the regional ethical vetting board of Stockholm, Sweden (register 
number 2009/1357-32 and amendment registry number 2014/1564-
32), and by the institutional review and ethics board of GZA Sint-
Augustinus (Wilrijk, Belgium). Informed consent was obtained in all 
cases excluding samples from the Tampere cohort, where, according 
to Finnish law, in cases in which informed consent cannot be obtained 
as a result of studies involving large retrospective materials or patients 
who have died before study, permission can be given by the National 
Authority for Medicolegal Affairs.
Further information can be found in Supplemental Methods, avail-
able online with this article; https://doi.org/10.1172/JCI93566DS1.
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Methods
ChIP sequencing. ChIP was performed as described previously (88). 
Briefly, 8 × 106 to 10 × 106 cells were cross-linked with 1% formalde-
hyde for 10 minutes at room temperature. Nuclei were extracted using 
LB3 buffer (10 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA 
[pH 8.0], 0.5 mM EGTA [pH 8.0], 0.1% Na-deoxycholate, 0.5% N- 
lauroylsarcosine), and chromatin was sheared to 200–700 bp using 
Covaris E220 Focused Ultrasonicator (Covaris). E2F1 antibodies for 
ChIP assays were purchased from BD Pharmingen (catalog 554213) 
and Santa Cruz Biotechnology (sc-193). The ChIP-Seq libraries were 
constructed using the ThruPLEX-FD Prep Kit (Rubicon Genom-
ics) with approximately 10 ng of ChIP DNA. Final products were 
sequenced on the NextSeq 500 at the Molecular Biology Core Facili-
ties of Dana-Farber Cancer Institute. ChIP-Seq data have been depos-
ited in the GEO repository under the accession number GSE94958.
RNA sequencing. RNA-Seq samples were prepared as described pre-
viously (47). Briefly, total RNAs were extracted and purified using the 
TRIzol reagent and RNeasy Mini Kit (Qiagen) according to the manufac-
turer’s instructions. RNA-Seq libraries were constructed using TruSeq 
RNA Sample Prep Kit v2 (Illumina, RS-122-2001) and then sequenced 
on the NextSeq 500 at the Molecular Biology Core Facilities of Dana-
Farber Cancer Institute. RNA-Seq data have been deposited in the GEO 
repository under the accession number GSE94863.
ATAC-Seq. ATAC-Seq was performed as previously described 
(89). Briefly, cells were plated and treated as indicated by the condi-
tion. Next, 75,000 cells were collected and lysed in ATAC lysis buffer. 
Cells were then resuspended in the transposition reaction mix, and the 
transposition reaction was incubated at 37°C for 30 minutes. Trans-
posed DNA was purified using AMPure purification methods as speci-
fied by the manufacturer (Agencourt). Purified DNA was then ampli-
fied using custom barcoded Nextera primers as previously reported 
and available in Buenrostro et al. (89). Library size and quality were 
validated using a Bioanalyzer and libraries sequenced on a NextSeq 
500. ATAC-Seq data have been deposited in the GEO repository 
under the accession number GSE105116.
Androgen stimulation. In androgen stimulation conditions, cells 
were cultured in 5% charcoal dextran–treated (CDT-treated) media 
for 72 hours before treatment with 10 nm DHT or vehicle (EtOH) for 3 
hours prior to harvest.
Quantitative PCR. Quantitative PCR (qPCR) analysis for occu-
pancy was performed as previously described for both ChIP-qPCR 
and reverse transcription qPCR (47, 88).
Immunoblot analysis. Cells were plated in CDT for 72 hours before 
harvest. Cell lysates were generated and immunoblot performed as 
previously described (68). Antibodies used were as follows: RB (BD 
Pharmingen, 554136), E2F1 (Santa Cruz Biotechnology, sc-193), GAP-
DH (Santa Cruz Biotechnology, sc-25778), p780-RB (Cell Signaling 
Technology, 3590S).
Statistics. Statistical analyses were performed as described above. 
Briefly, IHC correlations were calculated by Spearman correlation, 
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